PALB2 and cancer: We therefore sought to determine the incidence of germline PALB2 mutations in a larger series of 201 CDKN2A and CDK4 mutation-negative melanoma families, including 63 with confirmed cases of breast, pancreatic, or multiple other types of cancer.